Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355


SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Q2 2020: Probi raises long-term financial targets

share with twitter share with LinkedIn share with facebook
07/17/2020 | 02:02am EDT

Significant events during the second quarter

· The Board has decided on new financial targets and dividend policy
· Net sales amounted to SEK 180 m (SEK 176 m adjusted for currency changes), on par with the previous year. The EBITDA margin was 32% (31%) and the overall effect of Covid-19 was neutral.
· Bengt Jeppsson received the NutraChampion award in the Nutra Ingredients Awards

CEO's comments

Good business momentum in Q2

We continued to be strong during the second quarter and matched a strong comparative quarter last year when we also had a one-off income of SEK 4 m. Growth for the first half of the year was 6%. The EBITDA margin increased during the second quarter following a weaker start to the year and amounted to 32.3%.

The effects on Probi from Covid-19 have, overall, been limited in terms of both revenue and costs. The underlying demand for probiotics has increased in the US over the period, which can be partly explained by a greater interest in personal health in connection with Covid-19. We have seen an increase in demand from customers with a significant presence in the e-commerce sector, especially in the US. Thanks to our flexibility and experience, we have been able to quickly respond to this customer shift towards e-commerce. The product update carried out with one of our major customers in the US will have a positive contribution to our sales in the third quarter. At the same time, we expect this product line update to potentially cause some sales volatility in individual quarters to come.

In EMEA and APAC, which had relatively extensive restrictions as a result of Covid-19, sales have temporarily increased since customers ensured access to products, which has led to stock building up with some of our customers.

We are raising our ambitions

During the first half of 2020 the Board and management have completed a strategic review of the company's financial goals. We see clear trends driving the interest in, and use of, probiotics. A continued greater focus on personal health, increased life expectancy and new areas of application for probiotics are some examples. Probi is well-positioned to be a world leader in the probiotics market, especially in the premium segment where we have a solid research base. Probi's strong financial position gives us the opportunity to actively evaluate acquisitions that can strengthen and complement our existing product areas and geographical presence. We are raising our ambitions for growth, both organically and through acquisitions, but we will not lose focus on profitability and will also increase our EBITDA target. At the same time, the Board has decided on a new dividend policy.

It is with pride that I would also like to congratulate Bengt Jeppsson, one of Probi's founders, for the NutraChampion award in the Nutra Ingredients Awards. Bengt is a source of inspiration and very important in Probi's development into the top-quality probiotic company it is today.

The Covid-19 crisis is far from over, something also reflected in our different regions. At the same time, I can see that the interest in our products remains strong and that we do not currently see any indications that this will decline. I am therefore looking forward with confidence and humility to a continued good business momentum over the remainder of 2020.

Tom Rönnlund, CEO

Invitation to teleconference
Date: July 17, 2020
Time: 10:00 a.m. (CET)
Phone: +46 (0)8 50 55 83 59
Participants from Probi:
Tom Rönnlund, CEO
Henrik Lundkvist, CFO
The presentation is available at www.probi.com and www.financialhearings.com

Tom Rönnlund, CEO: Phone: +46 (0)46 286 89 40, E-mail: trd@probi.com
Henrik Lundkvist, CFO: Phone: +46 (0)46 286 89 41, E-mail: henrik.lundkvist@probi.com

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 17, 2020 at 08:00 CET. This a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.



(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 1.59% 352 Delayed Quote.56.08%
SYMRISE AG 0.64% 118.25 Delayed Quote.25.27%
share with twitter share with LinkedIn share with facebook
All news about PROBI AB (PUBL)
08/27PROBI : New clinical results on stress from Probi and their probiotic strain L. ..
07/17Q2 2020 : Probi raises long-term financial targets
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
07/02PROBI PUBL : and Örebro University to collaborate on research into exploration o..
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
05/13PROBI PUBL : ´s Annual General Meeting 2020
05/13PROBI PUBL : Annual General Meeting 2020
04/24Q1 2020 : A solid start to the year
More news
Sales 2020 671 M 74,3 M 74,3 M
Net income 2020 92,0 M 10,2 M 10,2 M
Net cash 2020 284 M 31,4 M 31,4 M
P/E ratio 2020 42,0x
Yield 2020 0,45%
Capitalization 3 948 M 435 M 438 M
EV / Sales 2020 5,47x
EV / Sales 2021 4,94x
Nbr of Employees -
Free-Float 38,9%
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts 2
Average target price 420,00 SEK
Last Close Price 346,50 SEK
Spread / Highest target 21,2%
Spread / Average Target 21,2%
Spread / Lowest Target 21,2%
EPS Revisions
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)56.08%435
BY-HEALTH CO., LTD.25.60%4 749
MEDIFAST, INC.51.04%1 938